Interestingly, we found increased levels of proinflammatory intermediate CD14++CD16+ monocytes in CRS-2 patients as compared to CKD patients, albeit no significant differences were detected between other robust markers of inflammation, such as CRP or ESR between the two cohorts. This evidence concerns the gene CRP and chronic kidney disease.